Neurocrine price target raised to $185 from $170 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $185 from $170 and keeps an Overweight rating on the shares. The share price is up 32% from 12-month lows in early October and up 19% since the mid-December approval of Crenessity, notes the analyst, who adds that investors the firm speaks with “give little to no credit” for major depression. However, the firm believes “this dislocation could resolve this year,” the analyst added.